Using subjective cognitive decline to identify high global amyloid in community‐based samples: A cross‐cohort study. Issue 1 (1st December 2019)

• Record Type: Journal Article
• Authors: Buckley, Rachel F.; Sikkes, Sietske; Villemagne, Victor L.; Mormino, Elizabeth C.; Rabin, Jennifer S.; Burnham, Samantha; Papp, Kathryn V.; Doré, Vincent; Masters, Colin L.; Properzi, Michael J.; Schultz, Aaron P.; Johnson, Keith A.; Rentz, Dorene M.; Sperling, Reisa A.; Amariglio, Rebecca E.
• Is Part Of: Alzheimer's & dementia. Volume 11:Issue 1(2019)
• Page Start: 670
• Page End: 678
• Publication Date: 2019-12-01
• Subjects: Subjective cognitive decline -- Amyloid -- APOEε4 -- Alzheimer's disease; Alzheimer's disease -- Periodicals; Alzheimer's disease -- Diagnosis -- Periodicals; Dementia -- Periodicals; Dementia -- Diagnosis -- Periodicals; 616.831
• DOI: 10.1016/j.dadm.2019.08.004
• Languages: English
• ISSNs: 2352-8729

Abstract

Abstract: Introduction: We aimed to examine the contribution of subjective cognitive decline (SCD) to reduce the number of β‐amyloid (Aβ) positron emission tomography scans required for recruiting Aβ+ clinically normal individuals in clinical trials. Methods: Three independent cohorts (890 clinically normal: 72 yrs ± 6.7; Female: 43.4%; SCD+: 24%; apolipoprotein E [ APOE ] ε4+: 28.5%; Aβ+: 32%) were used. SCD was dichotomized from one question. Using logistic regression, we classified Aβ+ using the SCD dichotomy, APOE ε4, sex, and age. Results: SCD increased odds of Aβ+ by 1.58 relative to non‐SCD. Female APOE ε4 carriers with SCD exhibited higher odds of Aβ+ (OR = 3.34), whereas male carriers with SCD showed a weaker, opposing effect (OR = 0.37). SCD endorsement reduces the number of Aβ positron emission tomography scans to recruit Aβ+ individuals by 13% and by 9% if APOE ε4 status is known. Conclusion: SCD helps to classify those with high Aβ, even beyond the substantial effect of APOE genotype. Collecting SCD is a feasible method for targeting recruitment for those likely on the AD trajectory. Highlights: SCD can significantly identify high Aβ beyond basic demographics and APOE ε4. Female APOE ε4 carriers with SCD have greater odds for high Aβ relative to males. SCD+ reduces the number of Aβ‐PET scans required by approximately 13%.